Peptide receptor radionuclide therapy with (177)Lu DOTATATE in a case of recurrent carotid body paraganglioma with spinal metastases

Clin Nucl Med. 2014 May;39(5):440-1. doi: 10.1097/RLU.0000000000000273.


Paragangliomas are rare benign neuroendocrine tumors, and 80% of all paragangliomas are either carotid body tumors or glomus jugulare tumors. We present a case of recurrent unresectable carotid body paraganglioma with nodal and T7 vertebral metastases in a 30-year-old man 6 years postsurgery detected with Ga DOTANOC PET/CT and was administered with peptide receptor radionuclide therapy using Lu DOTATATE. After 5 cycles of Lu DOTATATE (total cumulative activity of 750 mCi [27 GBq]), significant response at the primary site on Ga DOTANOC PET/CT and complete disappearance of nodal and T7 vertebral metastases were noted.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carotid Body Tumor / complications
  • Carotid Body Tumor / diagnostic imaging*
  • Carotid Body Tumor / drug therapy*
  • Humans
  • Male
  • Neoplasm Recurrence, Local / complications
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Paraganglioma / complications
  • Paraganglioma / diagnostic imaging*
  • Radionuclide Imaging
  • Spinal Neoplasms / complications
  • Spinal Neoplasms / diagnostic imaging*
  • Spinal Neoplasms / secondary*


  • Organometallic Compounds
  • lutetium Lu 177 dotatate
  • Octreotide